Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 34 points (0.2%) at 16,956 as of Friday, June 20, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,547 issues advancing vs. 1,406 declining with 177 unchanged.

The Health Services industry currently is unchanged today versus the S&P 500, which is up 0.1%. On the negative front, top decliners within the industry include Opko Health ( OPK), down 2.0%, Medtronic ( MDT), down 1.0%, Grifols ( GRFS), down 0.9% and Covidien ( COV), down 0.8%. Top gainers within the industry include Mettler-Toledo International ( MTD), up 2.2%, HCA Holdings ( HCA), up 1.7%, Smith & Nephew ( SNN), up 0.9%, Stryker Corporation ( SYK), up 0.8% and Agilent Technologies ( A), up 0.7%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. ResMed ( RMD) is one of the companies pushing the Health Services industry lower today. As of noon trading, ResMed is down $1.39 (-2.6%) to $51.80 on average volume. Thus far, 620,298 shares of ResMed exchanged hands as compared to its average daily volume of 873,300 shares. The stock has ranged in price between $51.12-$52.95 after having opened the day at $52.48 as compared to the previous trading day's close of $53.19.

ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. ResMed has a market cap of $7.4 billion and is part of the health care sector. Shares are up 13.0% year-to-date as of the close of trading on Thursday. Currently there are 4 analysts that rate ResMed a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates ResMed as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, increase in stock price during the past year and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full ResMed Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, DaVita HealthCare Partners ( DVA) is down $0.38 (-0.5%) to $71.20 on light volume. Thus far, 362,975 shares of DaVita HealthCare Partners exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $71.16-$71.94 after having opened the day at $71.80 as compared to the previous trading day's close of $71.58.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease. It operates kidney dialysis centers and provides related lab services primarily in outpatient dialysis centers and in contracted hospitals. DaVita HealthCare Partners has a market cap of $15.1 billion and is part of the health care sector. Shares are up 13.0% year-to-date as of the close of trading on Thursday. Currently there are 8 analysts that rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, notable return on equity and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full DaVita HealthCare Partners Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Boston Scientific ( BSX) is down $0.08 (-0.6%) to $12.58 on average volume. Thus far, 6.4 million shares of Boston Scientific exchanged hands as compared to its average daily volume of 12.7 million shares. The stock has ranged in price between $12.45-$12.74 after having opened the day at $12.69 as compared to the previous trading day's close of $12.66.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. Boston Scientific has a market cap of $16.7 billion and is part of the health care sector. Shares are up 5.3% year-to-date as of the close of trading on Thursday. Currently there are 11 analysts that rate Boston Scientific a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Boston Scientific as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Boston Scientific Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null